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Isolation and characterisation of toxin A-negative, toxin B-positive
Clostridium difficile in Dublin, Ireland
D. Drudy1, N. Harnedy2, S. Fanning1, R. O’Mahony1 and L. Kyne2
1

Centre for Food Safety, School of Agriculture, Food Science and Veterinary Medicine, University
College Dublin, and 2Department of Medicine for the Older Person, Mater Misericordiae Hospital,
Dublin, Ireland

ABSTRACT
Clostridium difficile is a major cause of infectious diarrhoea in hospitalised patients. Most pathogenic C.
difficile strains produce two toxins, A and B; however, clinically relevant toxin A-negative, toxin Bpositive (A–B+) strains of C. difficile that cause diarrhoea and colitis in humans have been isolated
worldwide. The aims of this study were to isolate and characterise A–B+ strains from two university
hospitals in Dublin, Ireland. Samples positive for C. difficile were identified daily by review of ELISA
results and were cultured on selective media. Following culture, toxin-specific immunoassays, IMR-90
cytotoxicity assays and PCR were used to analyse consecutive C. difficile isolates from 93 patients. Using
a toxin A-specific ELISA, 52 samples produced detectable toxin. All isolates were positive using a toxin
A ⁄ B ELISA. Similarly, all isolates were positive with the cytoxicity assay, although variant cytopathic
effects were observed in 41 cases. PCR amplification of the toxin A and toxin B genes revealed that 41 of
the previous A–B+ strains had a c. 1.7-kb deletion in the 3¢-end of the tcdA gene. Restriction enzyme
analysis of these amplicons revealed the loss of polymorphic restriction sites. These 41 A–B+ isolates
were designated toxinotype VIII by comparison with C. difficile strain 1470. PCR ribotyping revealed that
all A–B+ isolates belonged to PCR-ribotype 017. A–B+ C. difficile isolates accounted for 44% of the isolates
examined in this study, and appeared to be isolated more frequently in Dublin, Ireland, than reported
rates for other countries.
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INTRODUCTION
Clostridium difficile is a common nosocomial
pathogen and a major cause of infectious diarrhoea among hospitalised patients [1,2]. Colonisation with C. difficile is associated with a wide
spectrum of clinical presentations, ranging from
asymptomatic carriage to fulminant pseudomembranous colitis [3]. Recently, several institutions
worldwide have reported an increase in the
incidence of severe disease caused by C. difficile
[4–7]. This may be related to several factors,
including the changing demographics of patients
admitted to hospitals, infection control policies,
Corresponding author and reprint requests: D. Drudy, Centre
for Food Safety, School of Agriculture, Food Science and
Veterinary Medicine, University College Dublin, Belfield,
Dublin 4, Ireland
E-mail: denise.drudy@ucd.ie

or the emergence of more virulent strains of C.
difficile with increased antimicrobial resistance
[7,8] (42nd Annual meeting of the Infectious
Disease Society of America, 2004, abstract LB-2).
Two structurally similar toxins, denoted A and
B, are the main virulence determinants linked
with C. difficile-associated disease (CDAD), and
most pathogenic strains of C. difficile produce both
toxins (A+B+) [9,10]. The role of these toxins in the
pathogenesis of CDAD has been well-described
[10]. Both toxin A and toxin B are pro-inflammatory, cytotoxic and enterotoxic in the human colon
[11,12]. These toxins are encoded by two genes,
tcdA and tcdB, that map to a 19.6-kb pathogenicity
locus (PaLoc) containing additional regulatory
genes [13]. C. difficile isolates with varying genetic
modifications within the PaLoc have been described [14,15]. These include variant C. difficile
isolates that produce functional toxin proteins

 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases

Drudy et al.

TcdA and TcdB, and toxin-variant isolates that
fail to produce detectable toxins [14,16–18].
Toxin A-negative, toxin B-positive (A–B+)
C. difficile strains were thought originally to be
non-pathogenic. However, several recent reports
have demonstrated their clinical importance
[19–21]. Although outbreaks caused by A–B+
C. difficile are rare, several sporadic cases of
infection and cases of pseudomembranous colitis
(PMC) have been documented from several countries [20–23], and estimated prevalence rates of
A–B+ C. difficile strains vary widely [24].
To date, four A–B+ strain types have been
reported. Two toxinotypes, type VIII (strain 1470)
and type X (strain 8864) have been well-described
[25,26]. Both of these strains are truncated in the
3¢-region of the repetitive domain of tcdA. In
addition, both strains have alterations in their
tcdB genes whereby restriction fragment length
polymorphisms (RFLPs) give rise to altered glucosylation of RHO proteins and induce a differential cytopathic effect (CPE) when variant toxin
B is compared with wild-type toxin B from A+B+
strains [27]. More recently, two additional A–B+
toxinotypes (type XVI and type XVII) have been
described in Asia [15]. The molecular mechanism
responsible for the absence of toxin A production
in these newer toxinotypes has not yet been
elucidated. Of the four A–B+ strain types, toxinotype VIII is considered to be the most clinically
significant, and has been associated with the three
reported outbreaks involving A–B+ C. difficile
[19,20].
The present study reports, for the first time, the
isolation of A–B+ C. difficile (PCR ribotype 017,
toxinotype VIII) from a number of healthcare
settings in Dublin, Ireland.

MATERIALS AND METHODS
C. difficile strains and patients
Between 1 February and 31 July 2004, all C. difficile toxinpositive faecal samples from new cases of C. difficile diarrhoea
at two major university-affiliated teaching hospitals in Dublin
(St Vincent’s University Hospital and the Mater Misericordiae
University Hospital) were investigated. These hospitals have
570 and 490 beds, respectively. Both hospitals test all samples
for which a C. difficile toxin assay is requested, in addition to
testing non-requested liquid stool specimens from all inpatients and outpatients aged >65 years. The Premier toxin
A ⁄ B ELISA (Meridian Bioscience Inc., Cincinnati, OH, USA),
which detects both toxins A and B, was used in both
laboratories for C. difficile toxin detection. Incidence rates at
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both hospitals were 7 ⁄ 1000 patient admissions for the period
of the study. While several repeat samples were collected from
patients throughout the investigation, only the first isolate
from each patient was included for analysis in this study. In
addition, 17 random samples from a third university hospital,
collected during the months of February and May, were
investigated, as well as six random samples acquired from
three general practice surgeries and three nursing homes.
Of 85 new C. difficile cases in the two university hospitals
during the study period, 15 samples were unavailable for
culture because of insufficient remaining specimen following
routine microbiological investigations. The remaining 70 faecal
samples were cultured on Cyloserine-Cefoxitin-Fructose Agar
(CCFA) (LIP, Galway, Ireland). Identification of C. difficile was
confirmed by morphology, Gram’s stain, odour and UV
fluorescence, and latex agglutination (Microgen Bioproducts,
Camberley, UK). C. difficile controls included strains VPI 10463
(A+B+), 630 (A+B+), 57267 (A+B+), 1470 (A–B+) and 8864 (A–B+).
A non-toxigenic strain (R10567) served as a negative control in
all experiments.
Detection of C. difficile toxins
Toxin-specific immunoassays and cytotoxicity assays were
used to determine in-vitro toxin production. C. difficile isolates
were inoculated into brain heart infusion (BHI) broth (Oxoid,
Basingstoke, UK) and were cultured anaerobically for 48 h.
Broth cultures were centrifuged, after which the supernatants
were filtered through 0.2-lM Acrodisc syringe filters (Pall
Corp., Portsmouth, UK) and stored at –20C for up to
3 months before analysis of toxin production. Toxin A was
detected using the C. difficile Tox A ELISA (Tech Laboratory,
Blacksburg, VA, USA) according to the manufacturer’s
instructions. The C. difficile Tox A ⁄ B ELISA (Tech Laboratory)
was used to detect the presence of toxin A and ⁄ or toxin B.
Toxin B was detected using a tissue culture cytotoxin assay
and the IMR-90 fibroblast cell line (CAMR, Salisbury, UK). In
brief, filtered bacterial supernatants were added to IMR-90
monolayers, after which cytotoxicity was determined by
examining for cell rounding after 24 and 48 h. The specificity
of the CPE was confirmed by neutralisation with Clostridium
sordellii antitoxin (Tech Laboratory).
Molecular analysis of tcdA and tcdB
The genes for toxins A and B, tcdA and tcdB, were characterised by PCR as described previously [14,28]. All primers were
synthesised commercially by MWG Biotech (Ebersberg, Germany). Genomic DNA was purified from overnight Schaedler
broth cultures of C. difficile using the Wizard Genomic DNA kit
(Promega, Madison, WI, USA), followed by quantification of
template DNA using the PicoGreen ds DNA Quantitation kit
(Molecular Probes, Eugene, OR, USA). Primer sequences and
restriction enzymes used for PCR and RFLP analysis, respectively, are shown in Table 1. The relative locations of the
toxinotyping primers on the C. difficile PaLoc are shown in
Fig. 1(A). All PCRs were performed on a Perkin-Elmer 2400
Thermal Cycler (Applied Biosystems, Foster City, CA, USA) in
final reaction volumes of 50 lL using conditions described
previously [28,29]. Amplified products were visualised following electrophoresis on conventional agarose 1.5% w ⁄ v gels
stained with ethidium bromide 0.5 mg ⁄ mL in 1 · TBE buffer
(89 mM Tris base, 89 mM boric acid, 2 mM EDTA). Gels were

 2006 Copyright by the European Society of Clinical Microbiology and Infectious Diseases, CMI, 13, 298–304

300 Clinical Microbiology and Infection, Volume 13 Number 3, March 2007

Size (bp)
for VPI 10463

Primer

Primer sequence

NK9
NK11
A1C
A2N
A2C
A3N
A3C
A4N
B1C
B2N
B2C
B3N
B3C
B4N

5’-CCACCAGCTGCAGCCATA-3’
5’-TGATGCTAATAATGAATCTAAAATGGTAAC-3’
5’-GGAGGTTTTTATGTCTTTAATATCTAAAGA-3
5’-CCCTCTGTTATTGTAGGTAGTACATTTA-3’
5’-TAAATGTACTACCTACAATAACAGAGGG-3’
5’-CTTGTATATAAATCAGGTGCTATCAATA-3’
5’-TATTGATAGCACCTGATTTATATACAAG-3’
5’-TTATCAAACATATATTTTAGCCATATATC-3’
5’-AGAAAATTTTATGAGTTTAGTTAATAGAAA-3’
5’-CAGATAATGTAGGAAGTAAGTCTATAG-3’
5’-ATAGACTTACTTCCTACATTATCTGAA-3’
5’-CATCTGTATAAATATTTGGTGAAATTAC-3’
5’-AATTTCACCAAATATTTATACAGATG-3’
5’-ATTTAACATATTTTTATCTATTCA-3’

Target gene
(region)

Restriction
enzyme

Table 1. Primers and restriction
enzymes used in this study

tcdA (A3)
1200
tcdA (A1)
3100
tcdA (A2)
2000
tcdA (A3)

EcoR1

tcdB (B1)

HincII

3100
3100
tcdB (B2)
2000
tcdB (B3)
2000

(A)

(B)

(C)

Fig. 1. (A) Schematic representation of the Clostridium difficile pathogenicity locus (PaLoc). The relative locations of the
primer sequences (Table 1) used to amplify regions of tcdA and tcdB are shown. (B) Example of an agarose 1.5% w ⁄ v gel
showing the amplicons from the A3 PCR assay using primer pair A3C and A4N targeted at the repeated sequences of tcdA.
The arrows, in descending order, correspond to the A+B+ amplicon (3100 bp) and the A–B+ amplicon (1500 bp) (see
Tables 1 and 2). Lanes: M, 1-kb DNA ladder; 1, (A+B+) VPI 10463; 2–6, A–B+ clinical isolates; 7, A–B+ control strain F-1470;
8–11, A+B+ clinical isolates; 12, A–B– control. (C) Example of an agarose 1.5% w ⁄ v gel showing restriction digest patterns of
the A3 fragments from (A) following digestion with EcoRI. Lane assignment as indicated for (B). A–B+ C. difficile strains
only show the RFLPs indicated by the filled arrow.

visualised and photographed using the Gel Doc 2000 system
(Bio-Rad, Hercules, CA, USA). Two PCR products, denoted A3
and B1, were selected for restriction enzyme analysis with
EcoRI and HincII (Promega). Digests were visualised as
described previously and strain toxinotypes were assigned
according to the restriction digest patterns obtained.
16–23S PCR ribotyping
PCR ribotyping was performed as described by Stubbs et al.
[30] with minor modifications. DNA fingerprints were stored
as tagged image file format (TIFF) files and imported into
BioNumerics software v.4.0 (Applied Maths, Sint-MartensLatem, Belgium). Dendrograms were created using the DICE
coefficient and the unweighted pair group method with

arithmetic mean (UPGMA) for cluster correlation using default
settings.

RESULTS
Between February and August 2004, C. difficile
isolates were cultured from the faeces of 93
symptomatic adult patients. Initially, these isolates were examined for in-vitro production of
toxins A and B. Using the Toxin A ELISA, 52
isolates produced detectable toxin A (Table 2).
The remaining 41 isolates tested negative.
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Table 2. Summary of results for
detection of A)B+ Clostridium difficile
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Primer pair and amplicon size (kb)
Toxigenic Toxin
Toxin
Cell culture
No. (%) of samples status
A ELISA A+B ELISA cytotoxicity Assay NK 9-11 A1 A2 A3
52 (56)
41 (44)

+ +

A B
A-B+

+
-

+
+

+
+a

1.2
0.7

b

3.1. 2.0 3.1
3.1. 2.0 1.5

B1 B2 B3

b

3.1 2.0 2.0
3.1 2.0 2.0

a

Variant cytopathic effect observed.
Shorter amplicon caused by deletion in tcdA.

b

However, when the Toxin A ⁄ B ELISA was used,
toxin production was detected with all isolates.
Furthermore, all isolates induced a CPE when
investigated using the cell culture cytotoxicity
assay (Table 2). The CPE observed for the 41
isolates that were negative in the toxin A ELISA
was atypical, demonstrating complete cell rounding of the fibroblast body with no cytoplasmic
extensions (data not shown).
All C. difficile isolates were investigated by
amplifying the tcdA gene with primer pair NK
9-NK 11 to detect genetic alteration(s) in the
3’-region (Table 1). Forty-one isolates carried a
deletion and yielded a shorter amplicon (700 bp)
than that produced from the reference strain VPI
10463 (1200 bp) (Fig. 1(A), Table 2). These unique
isolates were classified as toxin A–B+ and were
evaluated further by toxinotyping (PCR-RFLP),
involving six PCRs designed to amplify the
complete tcdA (A1, A2, A3) and tcdB (B1, B2, B3)
genes (Fig. 1(A)) [29,31]. In all 41 cases, there was
a c. 1.7-kb deletion in the 3’-region of the tcdA
gene (denoted by the open bar in Fig. 1(A); see
also Fig. 1(B) and Table 2). Amplification of
selected domains within the A1 and A2 regions
of tcdA and the B1, B2 and B3 regions of tcdB
showed no alterations in amplicon size in comparison with the control strain 10463 (A+B+)
(Table 2).
Restriction enzyme digests of the tcdA locus
revealed the loss of some restriction sites in these
A–B+ strains. Furthermore, the A3 amplicon could
not be digested by EcoRI (Fig. 1(C)). Similarly,
HincII digestion profiles of the B1 product were
consistent with the loss of one or more HincII
restriction sites (denoted by the hatched bar in
Fig. 1(A); see also Fig. 2). Based on these restriction patterns, all 41 isolates were designated as
toxinotype VIII, according to the toxinotyping
scheme of Rupnik et al. [14]. The C. difficile isolates
were analysed by 16–23S PCR ribotyping, producing DNA banding patterns of 10–15 bands,
ranging in size from c. 200–1500 bp. Analysis of
the banding patterns obtained for the 41 A–B+

Fig. 2. Amplicons and RFLPs in the tcdB1 locus. Example
of an agarose 1.5% w ⁄ v gel showing the restriction
patterns of B1 PCR amplicons following restriction digest
with HincII. Lanes: 1 and 6, A–B+ Clostridium difficile; 2 and
3, A+B+ C. difficile; 5, C. difficile VPI 10463; and M, 100-bp
molecular size marker. A–B+ C. difficile strains show RFLPs
indicated by the filled arrow.
Table 3. Distribution of A+B+ and A-B+ Clostridium difficile
isolates in two university hospitals in Dublin, Ireland
Hospital
Institution Identifier
Number of isolates
No. A+B+ C. difficile
% per institution
No of ribotypes
No. A-B+ C. difficile
% per institution
No of ribotypes

A
40
23
(57)
7
17
(43)
1

B
30
12
(40)
7
18
(60)
1

A, Mater Misericordiae University Hospital.
B, St Vincent’s University Hospital.

isolates showed clonality, with identical banding
patterns observed (data not shown). Ribotyping
analysis revealed nine distinct ribotypes among
the 35 A+B+ isolates (Table 3). There were seven
different ribotypes among the 23 A+B+ isolates
from hospital A, and seven ribotypes among the
12 A+B+ isolates from hospital B (data not shown).
There were five ribotypes that were common to
both university hospitals, while two distinct
ribotyping patterns were found in one hospital
only (data not shown).
Toxin A–B+ C. difficile strains were isolated from
44% of the patients in this study. The distribution
of the A–B+ isolates in the two university hospitals
is summarised in Table 3. A–B+ C. difficile strains
were recovered from patients in these two university hospitals, as well as from patients in a
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third university hospital and from three community specimens. In total, 75% (70 ⁄ 93) of all the
isolates examined were cultured from patients
attending the two large university hospitals
(Table 3), where the prevalence rates for A–B+
C. difficile isolates were 43% and 60%, respectively. Overall, 35 (50%) of 70 patients at the two
university hospitals were infected with A–B+
C. difficile (Table 3).
DISCUSSION
Toxin A-negative, toxin B-positive (A–B+)
C. difficile has been isolated from many institutions in several countries on four continents [24].
Varying prevalence rates have been reported: a
rate of 2% was reported in a multicentre study in
the USA following analysis of C. difficile isolates
from six clinical settings [32]; in the UK, a
prevalence rate of 3% was found among 43
isolates from nine of 35 hospitals that submitted
strains for typing to the Anaerobic Reference
Laboratory in Cardiff [33]; and in France, a rate of
3% for isolates from 25 different hospitals in Paris
was reported [34]. In contrast, A–B+ prevalence
rates as high as 39% have been described in a
Japanese study [35], and a recent study in Israel
reported A–B+ C. difficile rates of 56% [36].
C. difficile is cultured in 55% of European
laboratories, but culture rates per country vary
considerably, from 20% to 100% [37]. C. difficile is
not cultured routinely in Irish hospitals, giving
rise to a knowledge gap concerning the molecular
epidemiology of Irish C. difficile strain types and
the prevalence of A–B+ C. difficile. Limited typing
of isolates from previous outbreaks at two of the
participating institutions in the present study
suggested the presence of A–B+ C. difficile (PCR
ribotype 017) in both hospitals. Between March
1999 and January 2000, six (14%) of 42 isolates
from the third university hospital were A–B+,
while nine (60%) of 15 isolates from the Mater
Misericordiae University hospital were A–B+
between March 2001 and March 2003 (J. Brazier,
personal communication).
The overall frequency of A–B+ C. difficile isolates
in this study was higher (44%) than non-outbreak
rates reported for other countries [24]. This may
reflect the collection of isolates analysed. A
limitation of the present study was that 75% of
the isolates investigated were from two university
hospitals, in which the toxin variant strain

accounted for 43% and 60%, respectively, of the
isolates collected. These data may be biased by the
local epidemiology of C. difficile in these institutions, e.g., persistence of a clonal strain from an
outbreak that is known to have occurred during
2003 in the Mater Misericordiae hospitals, where
the incidence rate peaked at 20 cases ⁄ 1000 patient
admissions. However, to our knowledge, no
outbreak of A–B+ C. difficile occurred at St Vincent’s University hospital. Furthermore, analysis
of 50 C. difficile isolates collected at this hospital
between 1997 and 1998 revealed that 65% of
isolates characterised were clonal A+B+ strains
and that A–B+ C. difficile were not prevalent in this
hospital during that period (personal unpublished results). However, it is possible that A–B+
C. difficile may have replaced the predominant
A+B+ strain types in recent years. Similarly, an
Argentinian hospital reported that A–B+ strains
replaced A+B+ strains completely over a 4-year
period, with no variation in incidence or clinical
presentation of CDAD [38].
A further possible limitation of the present
study was the random nature with which samples
were collected from the third university hospital,
GP surgeries and nursing homes. However, these
additional data confirmed the presence of these
variant isolates in additional healthcare settings.
All isolates were collected in a non-epidemic
setting, as demonstrated by the stable incidence
rates of C. difficile at the two major centres;
however, the reasons for clonal spread and
persistence of these variant strain types remain
to be determined.
A recent survey by the ESCMID Study Group
on C. difficile found that 58% of laboratories
surveyed in eight European countries use diagnostic methods for C. difficile that can detect only
toxin A [37]. The hospitals collaborating in the
present study used diagnostic methods that
detect both toxin A and toxin B; it is therefore
unlikely that any cases of toxin-variant C. difficile
would not have been detected. Failure to use
standardised C. difficile diagnostic methods that
detect both toxin A and B could lead to significant
under-reporting of C. difficile. This is of particular
concern in countries in which the prevalence of
toxin A–B+ C. difficile strains is known to be high.
Furthermore, outbreaks described previously
have documented an increased severity of
C. difficile disease associated with these A–B+
isolates; the ability to clearly discriminate
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between variant and non-variant C. difficile therefore has direct clinical relevance in terms of
infection control management [19,20]. Standardised approaches to the investigation of C. difficile
are essential in order to increase understanding of
the factors leading to institutional outbreaks of
C. difficile.
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